Few areas in healthcare can unite stakeholders across industry, political leanings, and social status, quite like cancer. And with initiatives around the world ramping up collaborative efforts to combat the disease, what lies ahead for oncology?
Read on for key stories, including updates from the floor at ASCO, Daiichi Sankyo and AstraZeneca on the importance of collaboration for innovation in cancer care, Ribonexus on taking on the challenge of cancer drug resistance, Research Partnership on the burgeoning European oncology CAR-T market access space, and much more.
Collaboration between policymakers, pharma stakeholders, and patient groups is sparking innovation as cancer research pursues its final frontier.
Cancer Moonshot: A story of hope for oncology in the US
A year on from the launch of Cancer Moonshot 2.0, we take a look back at key achievements in the programmes journey towards advancing cancer research and treatment in the US.
Healthcare is a team sport: Tackling cancer inequalities in Europe
Daiichi Sankyo’s Markus Kosch and AstraZeneca’s Greg Rossi explore the importance of combining collective expertise to push the boundaries of what is possible in cancer care.
Heard on the pipeline: Technology in oncology
In this special round-up feature, pharmaphorum editor-in-chief Jonah Comstock hits the floor of ASCO 2023 to find out what the brightest minds in healthcare think the future holds for digital and AI technologies in cancer research.
War in the Blood: European oncology CAR-T market access
The battle is taking shape in the burgeoning European oncology CAR-T market access space. In this feature, Research Partnership reviews the market access opportunities and challenges encountered by CAR-Ts commercialised in the EU-4 and England.
CancerX looks to digital to solve cancer care access challenges
As part of the reignited Cancer Moonshot, CancerX aims to leverage digital technologies to tackle some of the biggest challenges in cancer. To find out more, pharmaphorum editor-in-chief Jonah Comstock caught up with the ringleaders behind the ambitious effort.
Phesi’s Dr Gen Li on unlocking the power of data in oncology
Digital analysis, empowered by artificial intelligence, is going to transform the planning and execution of projects, says Phesi’s Dr Gen Li, but more data does not automatically equal more knowledge.
Taking on the challenge of cancer drug resistance
While targeted therapies have improved cancer patient outcomes, their efficacy decreases over time as patients develop resistance to the treatments. Steven Powell, president of Ribonexus, explores promising avenues of attack to combat cancer drug resistance.
An oncology workforce fit for the future
The future oncology workforce of the NHS needs to be flexible, comprehensive, and inclusive to continue providing high-quality, patient-centered care. Here, MSD speaks to industry experts to garner their thoughts on the workforce of the future.
Around the world in pharma events
Keep up to date with important industry events taking place across the pharmaceutical industry with this interactive guide to upcoming conferences around the world.
Read Deep Dive: Oncology 2023 in full pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector. Subscribe to future issues of Deep Dive.